Jens Grueger

542 total citations
16 papers, 374 citations indexed

About

Jens Grueger is a scholar working on Economics and Econometrics, General Health Professions and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jens Grueger has authored 16 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 5 papers in General Health Professions and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jens Grueger's work include Health Systems, Economic Evaluations, Quality of Life (10 papers), Pharmaceutical Economics and Policy (8 papers) and Healthcare cost, quality, practices (3 papers). Jens Grueger is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (10 papers), Pharmaceutical Economics and Policy (8 papers) and Healthcare cost, quality, practices (3 papers). Jens Grueger collaborates with scholars based in United States, Switzerland and United Kingdom. Jens Grueger's co-authors include Johan L. Severens, Penny Mohr, Andrew Briggs, Gérard de Pouvourville, Louis P. Garrison, Adrian Towse, P.D. Siviero, Rick A. Vreman, Wim Goettsch and Claudine Sapède and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Health and Quality of Life Outcomes and Value in Health.

In The Last Decade

Jens Grueger

13 papers receiving 360 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jens Grueger United States 6 262 54 49 38 29 16 374
Sherif Abaza Hungary 8 120 0.5× 53 1.0× 35 0.7× 64 1.7× 21 0.7× 29 306
Claudine Sapède France 9 126 0.5× 27 0.5× 32 0.7× 45 1.2× 24 0.8× 13 351
Chiara Whichello United States 9 250 1.0× 141 2.6× 24 0.5× 7 0.2× 31 1.1× 25 432
Elizabeth Brouwer United States 10 90 0.3× 92 1.7× 54 1.1× 19 0.5× 39 1.3× 17 355
Jagdeep Singh India 11 37 0.1× 23 0.4× 71 1.4× 26 0.7× 9 0.3× 23 342
Jae‐Ho Lee South Korea 11 67 0.3× 107 2.0× 15 0.3× 27 0.7× 4 0.1× 33 298
Kathleen McDavid United States 11 80 0.3× 75 1.4× 12 0.2× 37 1.0× 13 0.4× 17 500
William N. Malatestinic United States 12 86 0.3× 11 0.2× 61 1.2× 192 5.1× 65 2.2× 53 516
Kira Seiger United States 8 60 0.2× 45 0.8× 10 0.2× 48 1.3× 6 0.2× 17 225
Muhammad Rafiq Sweden 6 118 0.5× 97 1.8× 15 0.3× 10 0.3× 14 0.5× 9 360

Countries citing papers authored by Jens Grueger

Since Specialization
Citations

This map shows the geographic impact of Jens Grueger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Grueger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Grueger more than expected).

Fields of papers citing papers by Jens Grueger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Grueger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Grueger. The network helps show where Jens Grueger may publish in the future.

Co-authorship network of co-authors of Jens Grueger

This figure shows the co-authorship network connecting the top 25 collaborators of Jens Grueger. A scholar is included among the top collaborators of Jens Grueger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Grueger. Jens Grueger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Grueger, Jens, et al.. (2025). Guidance for an Effective Approach to Integrated Evidence Planning in a Dynamic World. Clinical Pharmacology & Therapeutics. 117(4). 920–926.
2.
Tafuri, Giovanni, A. Bracco, & Jens Grueger. (2025). Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update. Expert Review of Pharmacoeconomics & Outcomes Research. 25(5). 639–645. 1 indexed citations
3.
Sullivan, Sean D., et al.. (2025). The consequences of pharmaceutical tariffs in the United States. Journal of Managed Care & Specialty Pharmacy. 31(6). 533–536. 1 indexed citations
4.
5.
Grueger, Jens, Amélie Anota, Nicolas Naïditch, et al.. (2023). Opportunities to improve the adoption of health-related quality of life evidence as part of the French Health Technology Assessment process. Health Research Policy and Systems. 21(1). 137–137. 2 indexed citations
6.
Cole, Amanda, Ain Aaviksoo, Jens Grueger, et al.. (2022). POSA207 Expert Consensus on Payment Models for Multi-Indication Therapies. Value in Health. 25(1). S141–S141. 2 indexed citations
7.
8.
Tafuri, Giovanni, A. Bracco, & Jens Grueger. (2021). Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. Expert Review of Pharmacoeconomics & Outcomes Research. 22(3). 381–389. 9 indexed citations
9.
Vreman, Rick A., Ad Schuurman, Claudine Sapède, et al.. (2019). Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions. Value in Health. 22(11). 1275–1282. 72 indexed citations
10.
11.
McKenna, Stephen P., Lynda Doward, David Meads, et al.. (2007). Quality of life in infants and children with atopic dermatitis: Addressing issues of differential item functioning across countries in multinational clinical trials. Health and Quality of Life Outcomes. 5(1). 45–45. 27 indexed citations
12.
Ellis, Charles N., et al.. (2006). Cost Effectiveness of Management of Mild-to-Moderate Atopic Dermatitis with 1%??Pimecrolimus Cream in Children and Adolescents 2???17 Years of Age. American Journal of Clinical Dermatology. 7(2). 133–139. 21 indexed citations
13.
Grueger, Jens & D van Assche. (2002). PES1 COST EFFECTIVENESS OF PIMECROLIMUS (ELIDEL) IN THE TREATMENT OF CHILDREN WITH ATOPIC DERMATITIS. Value in Health. 5(6). 556–556. 1 indexed citations
14.
Grueger, Jens, et al.. (2001). PDG7: THE LIFETIME DIRECT MEDICAL COSTS OF MANAGING DIABETES AND ITS COMPLICATIONS IN FRANCE. Value in Health. 4(6). 504–505. 4 indexed citations
15.
16.
Jaime, J., et al.. (2001). PDG5: MODELING THE IMPACT OF A NEW ORAL ANTI-DIABETIC TREATMENT ON DIABETES COMPLICATION COSTS IN FRANCE. Value in Health. 4(6). 504–504. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sherif Abaza Breakdown of academic impact, for papers by Claudine Sapède Breakdown of academic impact, for papers by Chiara Whichello Breakdown of academic impact, for papers by Elizabeth Brouwer Breakdown of academic impact, for papers by Jagdeep Singh Breakdown of academic impact, for papers by Jae‐Ho Lee Breakdown of academic impact, for papers by Kathleen McDavid Breakdown of academic impact, for papers by William N. Malatestinic Breakdown of academic impact, for papers by Kira Seiger Breakdown of academic impact, for papers by Muhammad Rafiq
Rankless by CCL
2026